On October 9, 2021, Hainan Wei Yi Pharmaceutical Co., Ltd., a subsidiary of Hong Kong Winhealth Pharma Group, passed the on-site inspections of both modern logistics and the drug handling Good Supply Practice (GSP) certification that launched by Hainan Provincial Food and Drug Administration (FDA) with "zero defects", and successfully obtained the Pharmaceutical Trade License.
establishment of Hainan Wei Yi Pharmaceutical Co., Ltd. (hereinafter referred to as "the company") is an important strategic layout for Hong Kong Winhealth Pharma Group (hereinafter referred to as "the Group") to actively participate in the construction of Hainan Free Trade Zone (Port). The establishment of the company has been preparing since March 2021. Under the leadership of Ms. Wang Qi, the general manager of the company, and the care and guidance of the group leaders and and corresponding competent departments, the whole company faculty has been continuously endeavoring to perfect the quality management system in strict accordance with the drug handling GSP and the Group's quality policy, which takes "Quality First and Clients First” as a guiding principle, so as to complete the preparation work with high standards and stringent requirements.
The company received on-site inspections on modern logistics and GSP certification conducted by GSP certification expert panel from Hainan Provician FDA on August 30 and September 4-5, 2021. With proper deployments of Ms. Wang Qi, all employees could corporately perform their full functions, and conscientiously follow the expert panel to implement the on-site certification inspection. The company's quality management systems, facilities and equipment, computerized operating systems and office environment have been highly praised by the expert panel. The Hainan Provincial FDA issued the announcement that the company has passed the certification on September 23, 2021, and on October 9, the Pharmaceutical Trade License was obtained.
Setting sails on a new journey, the company will constantly forge ahead to write its new stories. The successful passing of GSP certification embodies the care and support of Group leaders and the painstaking efforts of the whole faculty of the company. Thereafter, the company will take this opportunity to further consolidate the quality and safety management system and assemble a high-quality management team full of vitality and cohesion. Meanwhile, the company will make full use of the resource advantages of the Group and policy advantages of Hainan Free Trade Zone (Port) to further enhance cooperation with advanced drug production and R&D enterprises both at home and abroad, and strive to build the company into a leading pharmaceutical import and export enterprise in the Hainan Free Trade Zone.
About Winhealth Pharma
Hong Kong Winhealth Pharma Group is a China-based, global innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The Group has established long-term strategical cooperation with several leading biopharmaceutical companies all over the globe, including Immedica, Roche, Pfizer, Kyowa Kirin, Shionogi, Cumberland, Daiichi Sankyo, etc., developed a portfolio with unique diversity in products under final phase clinical trials and listed ones including orphan medicines and specialized drugs. With persistent effort, more and more innovative drugs will be introduced from all over the world. For more information, please visit http://www.winhealth.hk, or follow “Winhealth Pharma” on WeChat.
About Hainan Wei Yi
Hainan Wei Yi Pharmaceutical Co., Ltd., a subsidiary of Hong Kong Winhealth Pharma Group, is a company that strategically established in Hainan on March 15, 2021. The company is mainly engaged in Chinese Patent Medicine, chemical Active Pharmaceutical Ingredient (API) and its preparations, antibiotic API and its preparations, biochemical and biological products, etc. Adhering to the quality policy of "Quality First and Clients First", relying on the Group's resource advantages and the policy advantages of Hainan Free Trade Zone (Port), the company will further enhance its cooperation with advanced drug production and R&D enterprises both at home and abroad, continuously introduce all kinds of new drugs and technical products into Hainan, and endeavor to facilitate the Group with creating a leading ecosystem of tackling with illness, rare and unmet diseases in China and surrounding areas.